VistaGen Therapeutics, Inc.

As of July 8, 2024, VistaGen Therapeutics, Inc. is considered overvalued with a valuation grade of "does not qualify," reflecting poor investment appeal due to a negative ROE and significant underperformance compared to the S&P 500.

As of August 13, 2024, VistaGen Therapeutics, Inc. is considered overvalued and has been downgraded to "does not qualify" due to poor financial metrics, a negative P/E ratio, and a significant decline in stock returns compared to the S&P 500.

As of May 16, 2025, the technical trend is mildly bearish due to bearish weekly MACD and moving averages, despite mixed signals from monthly indicators.

As of March 2022, the management team of VistaGen Therapeutics, Inc. includes Jon Saxe (Independent Chairman), Dr. H. Ralph Snodgrass (President and Chief Scientific Officer), Shawn Singh (CEO), and Independent Directors Ann Cunningham, Dr. Jerry Gin, and Dr. Brian Underdown. They oversee the company's strategic direction and operations.

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. It has a market cap of $69.01 million and reported no net sales with a net loss of $14 million as of December 2024.

As of Jun 18, VistaGen Therapeutics, Inc. has a market capitalization of 69.01 million and reported net sales of 0.69 million with a net loss of 47.30 million over the last four quarters. Shareholder's funds were 114.29 million, and total assets were 123.65 million.